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Abstracts 397obstructive pulmonary disease (COPD), diabetes mellitus, coronary artery
disease (CAD), lack of statins on treatment (1 point each). We calculated
the total risk score as the sum of all risk factors’ points, and grouped them
into 4 categories. Another 334 asymptomatic patients were extracted from
two tertiary care medical centers to derive a validation cohort (VC). The
derivation cohort (DC) and VC were clinically similar in terms of age (74 vs.
72 years) and gender (males 66% vs. 63%). Among risk factors, they
differed only for CAD (20% vs. 30% P < 0.001) and statin therapy (44% vs.
60% P < 0.001). They were comparable as per diabetes (29% vs. 24%
P ¼ 0.09), mean creatinine (1.13 vs. 1.1 mg/dL, P ¼ 0.58) and COPD (13.2%
vs. 10.5%, 0.21).
Results: Median follow up was 56 months for DC and 65 months for VC.
Long term mortality was comparable among DC and VC: overall survival
was 98.9  0.4% vs. 96.7  0.1% at 1 year; 92.7  1.1% vs. 91  1.6% at 3
years and 84.7  1.7% vs. 85.2  2% at 5 years.When comparing groups, 5
years survival rate was 97  1.5% for patients with score 0e3, 88.4  2.2%
for score 4e7, 69.6  4.7% for score 8e11, and 48.1  13.5% for score
12 (P < 0.0001) in the DC (ﬁg. 1). Similarly in the VC we found a
95.5  2% 5 years survival for score 0e3, 89.5  2.7% for score 4e7,
65  6.1% for score 8e11 and 44.8  14.1% for score 12 (P < 0.0001).
Conclusion: Our scoring system is a simple, 6 variables clinical tool for
prediction of post-operative life expectancy. The score showed to predict
adequately the long-term survival in a validation cohort from two different
medical centers. Patients with a score >8 have a poor long term survival,
and the advantage of CEA in this subgroup is questionable.We believe that
our score may help clinicians while selecting asymptomatic patients who
would beneﬁt from CEA.
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Introduction: Randomized trials have reported contradictory ﬁndings
regarding outcomes after carotid artery stenting (CAS) versus carotid
endarterectomy (CEA). Despite this, the 2011 American Heart Association
(AHA) guidelines expanded CAS indications, partly because of data from the
Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), but
also because of improving outcomes in Industry-sponsored ‘high risk for
CEA’ CAS Registries. The aim of the current systematic review was to see
whether there was a parallel reduction in procedural risk after CAS in
contemporary administrative dataset registries.
Methods: PubMed/Medline, Embase and Cochrane databases were
systematically searched from January 1, 2008 until February 23, 2015 for
administrative dataset registries reporting outcomes after both CEA and
CAS.
Results: Twenty-one registries reported outcomes after >1,500,000
procedures. CAS had similar stroke/death rates with CEA in one registry
involving ‘average risk’ asymptomatic and in two registries involving
‘average risk’ symptomatic patients. Stroke/death rates after CAS were
signiﬁcantly higher than CEA in 9/15 registries involving ‘average risk’
asymptomatic and in 11/18 registries involving ‘average risk’ symptomatic
patients. In ﬁve registries, CAS was associated with higher stroke/death
rates than CEA for both symptomatic and asymptomatic patients, but
formal statistical comparison was not reported. CAS was associated with
stroke/death rates that exceeded risk thresholds recommended by the AHA
in 9/15 registries involving ‘average risk’ asymptomatic patients and in 13/
18 registries involving ‘average risk’ symptomatic patients. In 5/18 regis-
tries, the procedural risk after CAS in ‘average risk’ symptomatic patients
exceeded 10%.
Conclusion: Data from contemporary administrative dataset registries
suggest that stroke/death rates following CAS remain signiﬁcantly higher
than after CEA and frequently exceed accepted AHA thresholds. In this
systematic review, there was no evidence of a sustained decline in pro-
cedural risk after CAS. The extremely high published risks in some
symptomatic registries suggest that clinical governance is not being ap-
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Introduction: Clopidogrel has provided signiﬁcant reduction in major
vascular events in patients with peripheral artery disease (PAD), particu-
larly among those following PTA. Clopidogrel antiplatelet effects differ
according to genotype ABCB1 and CYP2C19, establishing normal, inter-
mediate and poor metabolizers; and good or bad carriers. Intermediate and
poor metabolizers (CYP2C19 *1/*2,*2/*2) and bad transporters (ABCB1TT)
are responsible for the poor antiplatelet drug response. These poly-
morphisms have been associated with differences in clopidogrel response
in acute coronary syndrome patients but effects in peripheral artery dis-
ease are still understudied.
To determine the onset of ischemic vascular events requiring reopera-
tion of the affected limb or amputation in patients undergoing PTA (+/-
stent) during one year after treatment and to study the association with
the presence of genetic polymorphisms CYP2C19 and ABCB1 (separately
and combined) a case-control study was performed.
Methods: 72 patients with PAD of the lower limbs under PTA (+/- stent)
and treated with clopidogrel were selected. CYP2C19*2 (rs4244285),
CYP2C19*3 (rs4986893) and ABCB1 (rs1045642) polymorphisms were
genotyped using Taqman allelic discrimination technique to compare post-
operative results.
Results: Out of the 72 patients included in the study, 18 were
CYP2C19*2 allele carries, no patient carried CYP2C19*3 allele and 14 pa-
tients were ABCB1TT genotype. Out of the 72 patients, 25 (34.7%) had an
event during follow up (1 year). Patients with at least some loss of function
had a higher rate of events compared to patients with no loss of function
allele (OR ¼ 5.0, 95% CI 1.75 e14.27, p ¼ 0.003), and patients with some
loss of function allele were associated with a worse Fontaine evolution
(OR ¼ 13.96, 95% CI 4.44e43.82, p < 0.0001). Reduced and non metab-
olizer patients also had a higher rate of events compared to good
metabolizer patients (OR ¼ 4.49, 95% CI 1.25 e13.84, p ¼ 0.009) and a
worse outcome Fontaine grade (OR ¼ 8.31, 95% CI 2.36e29.16;
p ¼ 0.001). However, poor transporter patients didn’t show a statistically
signiﬁcant higher rate of events comparing to good transporters although
they showed a worse Fontaine grade evolution (OR ¼ 4.75, 95% CI 1.32e
17.07, p ¼ 0.017)
Conclusion: Poor metabolizer patients of clopidogrel have a higher
risk of major ischemic events and worst Fontaine grade evolution. Our
results support the role of CYP2C19 and ABCB1 polymorphisms as ge-
netic markers for vascular events in patients with peripheral vascular
disease of the lower limbs undergoing PTA and treated with clopidog-
rel.
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Introduction: Angiogenesis, the sprouting of new capillaries from the
microvasculature, improves blood perfusion of ischemic tissue. Various pro-
angiogenic factors have the potential to stimulate and enhance angio-
genesis. However, due to poor drug delivery and rapid clearance, clinical
trials on pro-angiogenic therapeutics in peripheral arterial disease have
only been marginally successful. We aimed to develop a polymer-based
drug delivery platform enabling local, sustained delivery of pro-angiogenic
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component.
Methods: Polymeric PEA microspheres were prepared and loaded with
VEGF. The release of VEGF from these microspheres, in both cell culture
medium and human serum at 37C was followed over time. VEGF con-
centrations were analyzed by ELISA; biological activity of the released VEGF
was assessed using proliferation assays on human umbilical vein endo-
thelial cells (HUVECs). VEGF-loaded microspheres were investigated for
their pro-angiogenic potential in vivo, either in matrigel plugs or by
intramuscular injection after induction of hindlimb ischemia in mice.
Neovascularization was monitored by immunohistochemistry and Laser
Doppler Perfusion Imaging.
Results: Our experiments showed that VEGF remains stable and bio-
logically active during both fabrication and long-term storage of the mi-
crospheres. After re-suspension in either cell culture medium or human
serum, VEGF is released from the microspheres. An initial burst release
over 48 hours is followed by a gradual, sustained release over 2 weeks. The
released VEGF was able to induce proliferation of HUVECs with virtually no
loss of biological activity. In vivo, microspheres containing approximately
15 ng VEGF were able to induced angiogenesis similar to 250 ng of un-
protected VEGF in a matrigel plug assay in mice. After induction of hindlimb
ischemia, both VEGF and VEGF-loaded microspheres show a comparable
increase in blood ﬂow recovery. Immunohistochemical analyses however
show a stronger increase in the number of collateral arteries in the
adductor muscles of mice treated with VEGF loaded microspheres
compared to free VEGF.
Conclusion: VEGF can be loaded into polymeric PEA microspheres and
stored without loss of biological activity. Under physiological conditions, a
burst of VEGF is released over 48 hours, followed by sustained release of
VEGF over 2 weeks. VEGF-loaded microspheres showed an over tenfold
increase in angiogenic potential compared to free VEGF in vivo in matrigel
plugs. Furthermore the increase in number of collateral arteries in the
adductor muscles of mice subjected to hindlimb ischemia suggests a
beneﬁcial effect of sustained release of VEGF.
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Introduction: As options for open surgery in the treatment of great
saphenous vein (GSV) reﬂux, both UGFS (ultrasound guided foam sclero-
therapy) and EVLA (endovenous laser) have been used for years, but the
long-term results compared to open surgery are still unclear. In the current
study we analyzed the 5 year results of a RCT comparing UGFS, EVLA and
Surgery in the treatment of GSV reﬂux and varicose veins.
Methods: We randomized 233 patients from 2 hospitals who had
symptomatic GSV reﬂux in one leg for UGFS, EVLA or open surgery (ligating
and stripping the GSV). In total 196 patients from our hospital were
included and treated during 2008e2010. In EVLA and Surgery groups local
phlebectomies were done simultaneously when necessary. 5 years after the
treatment we invited all patients treated in our hospital to clinical control.
Prevalence of varicose veins, DD-ultrasound and patient satisfaction were
evaluated. Furthermore, information on the additional treatments for the
same leg during the follow up was recorded. 166 patients (UGFS n ¼ 68,
EVLA n ¼ 67, Surgery n ¼ 61) participated in the 5 year control (85% of the
patients originally treated in our hospital).
Results: After 5 years from UGFS, EVLA and Surgery, there was no reﬂux
in GSV DD in 50.8%, 89.5% and 95.9% respectively (UGFS vs. EVLA/Surgery
p < 0.01). The CEAP classiﬁcation was not signiﬁcantly associated with the
type of treatment, and neither was cosmetic satisfaction, experienced pain
caused by the varicosities, disability or the presence of oedema. However,
during the 5 year period 15.3% of the patients in the UGFS group had
gotten additional treatment (most often laser ablation of GSV and local
phlebectomies) compared to EVLA and Surgery groups (3.3% and 4.0%
respectively, p < 0.05 compared to UGFS-group). Furthermore, at 5 yearfollow, 22.0% of the patients in the UGFS group were assigned for addi-
tional treatment compared to 6.8% in EVLA group and 8.0% in Surgery
group (p < 0.05). The odds of needing a new treatment were 5.9 times
higher if treated with UGFS compared to EVLA, EVLA having the lowest
ratio of new treatment.
Conclusion: Even though there was no difference in subjective patient
satisfaction, UGFS resulted in more additional treatments and was asso-
ciated with signiﬁcantly more fully or partially reﬂuxing GSV’s after the
treatment. Therefore, we conclude that UGFS is not as feasible as EVLA or
open surgery.
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Introduction: Chronic venous disease (CVD) is a common and potentially
costly condition affecting a signiﬁcant proportion of the population. This
pilot randomised control trial investigates the effect of a neuromuscular
electrical stimulation (NMES) device that causes sequential contraction of
the foot and calf muscles in patients with CVD.
Methods: Twenty-two patients with CEAP C2-C4 venous disease
were randomised to a sham or test device. Patients were asked to use
the device for 30 minutes per day for 6 weeks. Haemodynamic mea-
surements (duplex ultrasound and laser doppler ﬂuximetry), limb vol-
ume (perometer), venous reﬁll time (digital photoplethysmography) and
quality of life outcome measures were measured at baseline and after 6
weeks.
Results: The mean age of participants was 62 years, BMI 28.6, with a
15:7 female preponderance. At week 0, there was a signiﬁcant improve-
ment in femoral vein haemodynamics (from baseline) whilst using the
device in the test compared to sham group (time averaged mean velocity
(TAMV) 102.4% versus -9.1%, p < 0.0001; volume ﬂow 107.9% versus
-3.7%, p < 0.0001; peak velocity 377.7% versus -6.7%, p < 0.0001). The
sham group demonstrated an increase in limb volume, which was pre-
vented with the use of the device in the test group (sham +2.0%,
p < 0.0001; test +0.8%; p ¼ 0.0623). There was no improvement in limb
volume in either the sham or test group over the 6 weeks (sham +0.7%,
p ¼ 0.16; test +2.3%, p ¼ 0.74). A non-statistically signiﬁcant improvement
in disease speciﬁc quality of life outcome measures (AVVQ) was observed
in the test group over the 6 weeks.
Conclusion: This trial demonstrated a signiﬁcant improvement in venous
haemodynamics and reduction in limb swelling with the test device
compared to the sham group following immediate usage. In addition, it had
a positive effect on quality of life outcome measures. The device is safe to
use as a home based adjunct in managing venous disease. Due to the small
sample size, some improvements were not statistically signiﬁcant and
subgroup analysis was not performed. Further trials are required to
determine optimal frequency of device usage and the effect on different
subgroups of patients with venous disease.
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Introduction: 3 e10% of the worldwide population is suffering from pe-
ripheral arterial disease and 1 e3% will ultimately develop critical limb
ischemia (CLI). In the presence of long lesions, a femorodistal bypass often
is the only option to avoid major amputation and secure a better quality of
life. The angiosome concept divides the foot into six anatomic regions
(angiosomes) fed by distinct source arteries arising from the posterior
tibial, anterior tibial and peroneal arteries. This study investigates whether
bypass to the artery directly feeding the ischemic angiosome has an impact
on wound healing, major amputation rate and mortality before healing was
obtained.
